论文部分内容阅读
作者研究含高滴度(1:640～1:1 280)抗单纯疱疹病毒(HSV)抗体的免疫球蛋白,治疗小儿疱疹性口炎的效果,治疗急性疱疹性口炎(AHS)20例(中型和重型各10例),年龄1～6岁,按标准有复发危险。治疗复发性疱疹性口炎(RHS,一年复发1～3次)30例(中型和重型各15例),年龄2～12岁。都经病毒学检查确诊。在治疗前、刚治疗后和治疗结束后12～16天检查血清抗HSV 抗体共3次,同时检查混合唾液 HSV 抗原3次。肌肉注射免疫球蛋白1～4次,隔日1次,每次1.5ml,局部贴敷苯佐卡因软膏,给予合理的营养。对照组28例,只给局部贴敷苯佐卡因软膏。治疗结果小儿对免疫球蛋白耐受性好,第1次注射后数小时体温趋于正常,全身症状明显减轻。结膜炎症状在第1次注射后数日内消失。治疗过程中,AHS 组未出现新疱疹,在口腔粘膜上皮形成后7～10天,局部淋巴腺炎消失。RHS 组只1例出现新疱疹。疱疹治愈时间比对照组缩短2～3天。治疗前AHS组的严重型比中型抗体水平低。AHS 组血清抗体水平低于 RHS 组(P<0.05～0.001)。刚治疗后,AHS 组抗体水平明显提高(P<0.001),RHS组抗体水平提高不明显(P>0.05)。治疗后12～15天,各组血清抗体水平仍保持着刚治疗后的水平。治疗前,80%～93%的唾液标本查出 HSV 抗原,治疗后只200%～46%查出。随诊12～16个月,
The authors investigated the effect of immunoglobulin with high titer (1: 640-1: 1 280) anti-herpes simplex virus (HSV) antibody in the treatment of pediatric herpetic stomatitis and in the treatment of 20 patients with acute herpetic stomatitis (AHS) Medium and heavy in 10 cases), aged 1 to 6 years old, according to the standard risk of relapse. Treatment of recurrent herpetic stomatitis (RHS, relapse 1 to 3 times a year) in 30 cases (15 cases of medium and heavy), aged 2 to 12 years. Virological examination confirmed. Serum anti-HSV antibodies were tested 3 times before treatment, immediately after treatment and 12-16 days after the end of treatment, and mixed salivary HSV antigen 3 times at the same time. Intramuscular injection of immunoglobulin 1 to 4 times, every other day 1, each 1.5ml, topical affixed benzocaine ointment, to give a reasonable nutrition. The control group of 28 cases, only topical affixed benzocaine ointment. Treatment outcome Children immunoglobulin tolerance, a few hours after the first injection of body temperature tends to be normal, significantly reduced systemic symptoms. Conjunctivitis symptoms disappear within a few days after the first injection. During the course of treatment, no new herpes appeared in the AHS group, and local lymphadenitis disappeared 7 to 10 days after the formation of oral mucosal epithelium. Only one case of new herpes appeared in the RHS group. Herpes cure time than the control group shortened 2 to 3 days. AHS group before treatment, severe type than the low level of antibodies. Serum antibody levels in AHS group were lower than those in RHS group (P <0.05 ~ 0.001). After treatment, antibody levels in AHS group were significantly increased (P <0.001), and antibody levels in RHS group were not significantly increased (P> 0.05). After 12 to 15 days of treatment, serum antibody levels of each group still maintained the level of just after treatment. Before treatment, HSV antigen was detected in 80% ~ 93% of the saliva samples, and only 200% ~ 46% of the samples were detected after treatment. Followed up for 12 to 16 months,